Probiotics and antibiotic-associated diarrhea in children: A review and new evidence on Lactobacillus rhamnosus GG during and after antibiotic treatment

Pharmacological Research

Volumn 128, Issue , 2018, Pages 63-72

  Mantegazza, Cecilia ^a   Molinari, Paola ^b   D'Auria, Enza ^a   Sonnino, Micol ^a   Morelli, Lorenzo ^b   Zuccotti, Gian Vincenzo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

Author keywords

Antibiotic associated diarrhea; Antibiotics; Children; Lactobacillus GG; Probiotics; Saccharomyces boulardii

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; ERYTHROMYCIN; ISOPENICILLIN N; KEFIR; MACROLIDE; PENICILLIN G; PENICILLIN V; PROBIOTIC AGENT; SULFAFURAZOLE; YOGHURT; ANTIINFECTIVE AGENT;

ABDOMINAL PAIN; ANTIBIOTIC ASSOCIATED DIARRHEA; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS; BLOATING; CHILD; CLOSTRIDIUM BUTYRICUM; CONSTIPATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG USE; ENDOCARDITIS; FLATULENCE; HUMAN; INFECTION; INFECTION RISK; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS DELBRUECKII SUBSP. BULGARICUS; LACTOBACILLUS PLANTARUM; LACTOBACILLUS REUTERI; LACTOBACILLUS RHAMNOSUS; MENINGITIS; NAUSEA; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SACCHAROMYCES BOULARDII; SIDE EFFECT; STREPTOCOCCUS THERMOPHILUS; TASTE DISORDER; THORAX PAIN; VOMITING; CHEMICALLY INDUCED; DIARRHEA;

ANTI-BACTERIAL AGENTS; CHILD; DIARRHEA; HUMANS; LACTOBACILLUS RHAMNOSUS; PROBIOTICS;

EID: 85028460691     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2017.08.001     Document Type: Review

References (93)

1. Gibson, M.K., Crofts, T.S., Dantas, G., Antibiotics and the developing infant gut microbiota and resistome. Curr. Opin. Microbiol. 27 (2015), 51–56.
2. Chai, G., Governale, L., McMahon, A.W., Trinidad, J.P., Staffa, J., Murphy, D., Trends of outpatient prescription drug utilization in US children, 2002–2010. Pediatrics 130:1 (2012), 23–31.
3. McFarland, L.V., Surawicz, C.M., Stamm, W.E., Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J. Infect. Dis. 84 (1990), 162–678.
4. Barbut, F., Meynard, J.L., Managing antibiotic associated diarrhoea. BMJ 324 (2002), 1345–1346.
5. Turck, D., Bernet, J.-P., Marx, J., Kempf, H., Giard, P., Walbaum, O., Lacombe, A., Rembert, F., Toursel, F., Bernasconi, P., Gottrand, F., McFarland, L.V., Bloch, K., Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population. J. Pediatr. Gastroenterol. Nutr. 37 (2003), 22–26.
6. McFarland, L.V., Epidemiology, risk factors and treatments for antibiotic associated diarrhea. Dig. Dis. 16 (1998), 292–307.
7. Kuehn, J., Ismael, Z., Long, P.F., Barker, C.I., Sharland, M., Reported rates of diarrhea following oral penicillin therapy in pediatric clinical trials. J. Pediatr. Pharmacol. Ther. 20:March-April (2) (2015), 90–104.
8. Beaugerie, L., Petit, J.C., Microbial-gut interactions in health and disease. Antibiotic-associated diarrhoea. Best Pract. Res. Clin. Gastroenterol. 18:April (2) (2004), 337–352 (Review).
9. McFarland, L.V., Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am. J. Gastroenterol. 101 (2006), 812–822.
10. Pant, C., Deshpande, A., Gilroy, R., et al. Rising incidence of Clostridium difficile related discharges among hospitalized children in the United States. Infect. Control Hosp. Epidemiol. 37 (2015), 104–106.
11. Hill, C., Guarner, F., Reid, G., et al. Expert consensus document, The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 11 (2014), 506–514.
12. Reid, G., Probiotics: definition, scope and mechanisms of action. Best Pract. Res. Clin. Gastroenterol. 30:February (1) (2016), 17–25.
13. Saxelin, M., LGG Summatim. 2002.
14. Teitelbaum, J.E., Walker, W.A., Nutritional impact of prea nd probiotics as protective gastrointestinal organisms. Annu. Rev. Nutr. 22 (2002), 107–138.
15. M. Rondanelli, M.A. Faliva, S. Perna, A. Giacosa, G. Peroni, A.M. Castellazzi, Using probiotics in clinical practice: where are we now? A review of existing meta-analyses, (https://www.ncbi.nlm.nih.gov/pubmed/286406622017).
16. Szajewska, H., Ruszczyníski, M., Radzikowski, A., Probiotics in the prevention of antibiotic-associated diarrhea in children: a meta-analysis of randomized controlled trials. J. Pediatr. 149 (2006), 367–372.
17. Goldenberg, J.Z., Lytvyn, L., Steurich, J., Parkin, P., Mahant, S., Johnston, B.C., Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst. Rev., 22(December (12)), 2015, CD004827.
18. Johnston, B.C., Goldenberg, J.Z., Parkin, P.C., Probiotics and the prevention of antibiotic-associated diarrhea in infants and children. JAMA(October (14)), 2016, 1484–1485.
19. McFarland, L.V., Huang, Y., Wang, L., Malfertheiner, P., Systematic review and meta-analysis: multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events. United Eur. Gastroenterol. J.(August (4)), 2016, 546–561.
20. Papamichael, K., Mantzaris, G.J., Pathogenesis of Helicobacter pylori infection: colonization, virulence factors of the bacterium and immune and non-immune host response. Nosokom Chron 7 (2012), 32–37.
21. Malfertheiner, P., Link, A., Selgrad, M., Helicobacter pylori: perspectives and time trends. Nat. Rev. Gastroenterol. Hepatol. 11 (2014), 628–638.
22. Delchier, J.C., Delchier, J.C., Thieroff-Ekerdt, R., Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of H. pylori. Aliment. Pharmacol. Ther. 40 (2014), 171–177.
23. Gisbert, J.P., Romano, M., Gravina, A.G., et al. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment. Pharmacol. Ther. 41 (2015), 768–775.
24. Jheng, G.H., Wu, I.C., Shih, H.Y., et al. Comparison of second-line quadruple therapies with or without bismuth for H. pylori infection. Biomed. Res. Int., 2015, 163–960.
25. Megraud, F., Coenen, S., Versporten, A., et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 62 (2013), 34–42.
26. Wang, Y.H., Huang, Y., Effect of Lactobacillus acidophilus and Bifidobacterium bifidum supplementation to standard triple therapy on Helicobacter pylori eradication and dynamic changes in intestinal flora. World J. Microbiol. Biotechnol. 30 (2014), 847–853.
27. Plewinska, E., Planeta-Malecka, I., Bak-Romaniszyn, L., et al. Probiotics in the treatment of Helicobacter pylori infection in children (Polish). Gastroenterol. Pol. 13 (2006), 315–319.
28. Tolone, S., Pellino, V., Vitaliti, G., et al. Evaluation of Helicobacter pylori eradication in pediatric patients by triple therapy plus lactoferrin and probiotics compared to triple therapy alone. Ital. J. Pediatr., 38, 2012, 63.
29. Goldenberg, J.Z., Ma, S.S., Saxton, J.D., Martzen, M.R., Vandvik, P.O., Thorlund, K., Guyatt, G.H., Johnston, B.C., Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst. Rev.(May (5)), 2013, CD006095.
30. Wolvers, D., Antoine, J.-M., Myllyluoma, E., Schrezenmeir, J., Szajewska, H., Rijkers, G.T., Guidance for substantiating the evidence for beneficial effects of probiotics: prevention and management of infections by probiotics. J. Nutr. 140 (2010), 698S–712S.
31. Szajewska, H., Kołodziej, M., Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults. Aliment. Pharmacol. Ther. 42:10 (2015), 1149–1157.
32. Segers, M.E., Lebeer, S., Towards a better understanding of Lactobacillus rhamnosus GG − host interactions. Microb. Cell Fact., 13, 2014, S7.
33. Yan, F., Polk, D.B., Lactobacillus rhamnosus GG: an updated strategy to use microbial products to promote health. Funct. Food Rev. 4 (2012), 77–84.
34. Fong, F.L., Kirjavainen, P.V., El-Nezami, H., Immunomodulation of Lactobacillus rhamnosus GG (LGG)-derived soluble factors on antigen-presenting cells of healthy blood donors. Sci. Rep., 6(March (10)), 2016, 22845.
35. Petrova, M.I., Imholz, N.C., Verhoeven, T.L., Balzarini, J., Van Damme, E.J., Schols, D., Vanderleyden, J., Lebeer, S., Lectin like molecules of Lactobacillus rhamnosus GG inhibit pathogenic Escherichia coli and Salmonella biofilm formation. PLoS One, 11(August (8)), 2016, e0161337.
36. Goldstein, E.J., Tyrrell, K.L., Citron, D.M., Lactobacillus species: taxonomic complexity and controversial susceptibilities. Clin. Infect. Dis. 60:Suppl. 2 (2015), 98–107.
37. Korpela, K., Salonen, A., Virta, L.J., Kumpu, M., Kekkonen, R.A., deVos, W.M., Lactobacillus rhamnosus GG intake modifies preschool children's intestinal microbiota, alleviates penicillin-associated changes, and reduces antibiotic use. PLoS One, 11(April (4)), 2016.
38. Fietto, J.L., et al. Molecular and physiological comparisons between Saccharomyces cerevisiae and Saccharomyces boulardii. Can. J. Microbiol. 50 (2004), 615–621.
39. Tiago, F.C., et al. Adhesion to the yeast cell surface as a mechanism for trapping pathogenic bacteria by Saccharomyces probiotics. J. Med. Microbiol. 61 (2012), 1194–1207.
40. Stier, H., Bischoff, S.C., Influence of Saccharomyces boulardii CNCM I-745on the gut-associated immune system. Clin. Exp. Gastroenterol. 9:September (13) (2016), 269–279 (eCollection 2016. Review.).
41. Lukaszewicz, M., Rigobelo, Everlon, (eds.) Probiotics, 2012, InTech (Ch. 16).
42. Kelesidis, T., Pothoulakis, C., Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Ther. Adv. Gastroenterol. 5 (2012), 111–125.
43. Pothoulakis, C., Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii. Aliment. Pharmacol. Ther. 30 (2009), 826–833.
44. Szajewska, H., Mrukowicz, J., Metaanalysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment. Pharmacol. Ther. 22 (2005), 365–372.
45. Szajewska, H., Kołodziej, M., Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment. Pharmacol. Ther. 42:October (7) (2015), 793–801.
46. Wan, C.M., Yu, H., Liu, G., Xu, H.M., Mao, Z.Q., Xu, Y., Jin, Y., Luo, R.P., Wang, W.J., Fang, F., A multicenter randomized controlled study of Saccharomyces boulardii in the prevention ofantibiotic-associated diarrhea in infants and young children. Zhonghua Er Ke Za Zhi 55:5 (2017), 349–354.
47. Reuter, G., The Lactobacillus and Bifidobacterium microflora of the human intestine: composition and succession. Curr. Issues Intest. Microbiol. 2 (2001), 43–53.
48. Rosander, A., Connolly, E., Roos, S., Removal of antibiotic resistance plasmids from Lactobacillus reuteri ATCC 55 730 and characterization of the resulting daughter strain, L. reuteri DSM 17938. Appl. Environ. Microbiol. 74 (2008), 6032–6040.
49. Schaefer, L., Auchtung, T.A., Hermans, K.E., Whitehead, D., Borhan, B., The antimicrobial compound reuterin (3-hydroxypropionaldehyde) induces oxidative stress via interaction with thiol groups. Microbiology 156:June (Pt 6) (2010), 1589–1599.
50. Jones, S.E., Versalovic, J., Probiotic Lactobacillus reuteri biofilms produce antimicrobial and antiinflammatory factors. BMC Microbiol., 11(9), 2009, 35.
51. Casas, I.A., Dobrogosz, W.J., Validation of the probiotic concept: Lactobacillus reuteri confers broad-spectrum protection against disease in humans and animals. Microb. Ecol. Health Dis 12 (2000), 247–285.
52. Casas, I.A., Dobrogosz, W.J., Validation of probiotic concept: L. reuteri confers broad-spectrum protection against disease in humans and animals. Microb. Ecol. Health Dis. 12 (2000), 247–285.
53. Urbańska, M., Gieruszczak-Białek, D., Szajewska, H., Systematic review with meta-analysis: Lactobacillus reuteri DSM 17938 for diarrhoeal diseases in children. Aliment. Pharmacol. Ther. 43:May (10) (2016), 1025–1034.
54. Georgieva, M., Pancheva, R., Rasheva, N., et al. Use of the probiotic Lactobacillus reuteri DSM 17938 in the prevention of antibiotic associated infections in Bulgarian children: a randomized, controlled trial. IMAB Annu. Proc. (Sci. Pap.) 21 (2015), 895–900.
55. Lionetti, E., Miniello, V.L., Castellaneta, S.P., Magistá, A.M., de Canio, A., Maurogiovanni, G., Ierardi, E., Cavallo, L., Francavilla, R., Lactobacillus reuteri therapy to reduce side-effects during anti Helicobacter pylori treatment in children:a randomized placebo cntrolled trial. Aliment. Pharmacol. Ther.(10), 2006, 1461–1468 (Epub 2006 Oct 10).
56. Kołodziej, M., Szajewska, H., Lactobacillus reuteri DSM17938 in the prevention of antibiotic associated diarrhoea in children:protocol of a randomised controlled trial. BMJ Open, 7(January (1)), 2017, e013928.
57. Hamer, H.M., Jonkers, D., Venema, K., Vanhoutvin, S., Troost, F.J., Brummer, R.-J., Review article: the role of butyrate on colonic function. Aliment. Pharmacol. Ther. 27:2 (2008), 104–119.
58. Ewaschuk, J.B., Diaz, H., Meddings, L., et al. Secreted bioactive factors from Bifidobacterium infantis enhance epithelial cell barrier function. Am. J. Physiol. Gastrointest. Liver Physiol. 295:5 (2008), 1025–1034.
59. Investigating Group for Prevention of AAD in Children with Pneumonia by Clostridium Butyricum and Bifidobacterium, Multicenter, randomized, controlled clinical trial on preventing antibiotic associated diarrhea in children with pneumonia using the live Clostridium butyricum and Bifidobacterium combined Powder. Zhonghua Er Ke Za Zhi 50:10 (2012), 732–736.
60. Mao, Y., Nobaek, S., Kasravi, B., Adawi, D., Stenram, U., Molin, G., et al. The effects of Lactobacillus strains and oat fiber on methotrexate-induced enterocolitis in rats. Gastroenterology 111 (1996), 334–344.
61. Molin, G., Probiotics in foods not containing milk or milk constituents, with special reference to Lactobacillus plantarum, 299 v. Am. J. Clin. Nutr. 73 (2001), 380–385.
62. Lönnermark, E., Friman, V., Lappas, G., Sandberg, T., Berggren, A., Adlerberth, I., Intake of Lactobacillus plantarum reduces certain gastrointestinal symptoms during treatment with antibiotics. J. Clin. Gastroenterol. 44 (2010), 106–112.
63. Olek, A., Woynarowski, M., Ahrén, I.L., Kierkuś, J., Socha, P., Larsson, N., Önning, G., Efficacy and safety of Lactobacillus plantarum DSM 9843 (LP299V) in the prevention of antibiotic associated gastrointestinal symptoms in children randomized, double-blind placebo-controlled study. J. Pediatr. 186 (2017), 82–86.
64. Khodadad, A., et al. Probiotics for the treatment of pediatric Helicobacter pylori infection: a randomized double blind clinical trial. Iran. J. Pediatr. 23 (2013), 79–84.
65. Correa, N.B.O., Peret Filho, L.A., Penna, F.J., et al. A Randomized formula controlled trial of Bifidobacterium lactis and Streptococcus thermophilus for prevention of antibiotic-associated diarrhea in infants. J. Clin. Gastroenterol. 39 (2005), 385–389.
66. Ruszczyński, M., Radzikowski, A., Szajewska, H., Clinical trial: effectiveness of Lactobacillus rhamnosus (strains E/N, Oxy and Pen) in the prevention of antibiotic-associated diarrhoea in children. Aliment. Pharmacol. Ther. 28 (2008), 154–161.
67. Szajewska, H., Canani, R.B., Guarino, A., Hojsak, I., Indrio, F., Kolacek, S., Orel, R., ESPGHAN Working Group for Probiotics Prebiotics, et al. Probiotics for the prevention of antibiotic associated diarrhea in children. J. Pediatr. Gastroenterol. Nutr. 62:3 (2016), 495–506.
68. Codex Committee on Milk and Milk Products, Codex Standard for Fermented Milks (CODEX STAN 243–2003), vol. 11, 2010, Codex Alimentarius, New Zealand.
69. Codex Alimentarius, Milk and Milk Products, second edition. Rome, 2011. http://www.fao.org/docrep/015/i2085e/i2085e00.pdf. Accessed May12, 2014.
70. Adolfsson, O., Meydani, S.N., Russell, R.M., Yogurt and gut function. Am. J. Clin. Nutr. 80 (2004), 245–256.
71. Meydani, S.N., Ha, W.K., Immunologic effects of yogurt. Am. J. Clin. Nutr. 71 (2000), 861–872.
72. Patro-Golab, B., Shamir, R., Szajewska, H., Yogurt for treating antibiotic-associated diarrhea:systematic review and meta-analysis. Nutrition 31:6 (2015), 796–800.
73. Fox, M.J., Ahuja, K.D., Robertson, I.K., Ball, M.J., Eri, R.D., Can probiotic yogurt prevent diarrhoea in children on antibiotics? A double-blind, randomised, placebo-controlled study. BMJ Open, 5(1), 2015.
74. Lopitz-Otsoa, F., Rementeria, A., Elguezabal, N., Garaizar, J., Kefir: a symbiotic yeasts-bacteria community with alleged healthy capabilities. Rev. Iberoam Micol. 23 (2006), 67–74.
75. Merenstein, D.J., Foster, J., D'Amico, F., A randomized clinical trial measuring the influence of kefir on antibiotic-associated diarrhea: the measuring the influence of Kefir (MILK) Study. Arch. Pediatr. Adolesc. Med. 163:8 (2009), 750–754.
76. Vandenplas, Yvan, Huys, Geert, Daube, Georges, Probiotics: an update. J. Pediatr. (Rio. J) 91:1 (2015), 6–21.
77. Klein, G., Antibiotic resistance and molecular characterization of probiotic and clinical lactobacillus strains in relation to safety aspects of probiotics. Foodborne Pathog. Dis. 8 (2011), 267–281.
78. Goldstein, E.J., Tyrrell, K.L., Citron, D.M., Lactobacillus species:taxonomic complexity and controversial susceptibilities. Clin. Infect. Dis. 60 (2015), 98–107.
79. Salminen, M.K., Rautelin, H., Tynkkynen, S., et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin. Infect. Dis. 38 (2004), 62–69.
80. Simkins, J., Kaltsas, A., Currie, B.P., Investigation of inpatient probiotic use at an academic medical center. Int. J. Infect. Dis. 17 (2013), 321–324.
81. van den Nieuwboer, M., Brummer, R.J., Guarner, F., Morelli, L., Cabana, M., Claassen, E., Safety of probiotics and synbiotic sin children under 18 years of age. Benef. Microbes 6:5 (2015), 615–630.
82. Broaders, E., Gahan, C.G., Marchesi, J.R., Mobile genetic elements of the human gastrointestinal tract: potential for spread of antibiotic resistance genes. Gut Microbes 4 (2013), 271–280.
83. Gueimonde, M., Sánchez, B., de Los Reyes-Gavilán, G., Margolles, A., Antibiotic resistance in probiotic bacteria. Front. Microbiol., 4, 2013, 202.
84. Drago, L., Mattina, R., Nicola, L., Rodighiero, V., De Vecchi, E., Macrolide resistance and in vitro selection of resistance to antibiotics in Lactobacillus isolates. J. Microbiol. 49 (2011), 651–656.
85. Zheng, M., Zhang, R., Tian, X., Zhou, X., Pan, X., Wong, A., Assessing the risk of probiotic dietary supplements in the context of antibiotic resistance. Front. Microbiol., 8, 2017, 908.
86. Martinez, R., Bedani, R., Saad, S., Scientific evidence for health effects attributed to the consumption of probiotics and prebiotics: an update for current perspectives and future challenges. Br. J. Nutr. 114 (2015), 1993–2015.
87. Tsuneki, H., Ishizuka, M., Terasawa, M., et al. Effect of green tea on blood glucose levels and serum proteomic patterns in diabetic (db/db) mice and on glucose metabolism in healthy humans. BMC Pharmacol. 4 (2004), 18–27.
88. Wang, X., Juan, Q.F., He, Y.W., Zhuang, L., Fang, Y.Y., Wang, Y.H., Multiple effects of probiotics on different types of diabetes: a systematic review and meta-analysis of randomized, placebo-controlled trials. J. Pediatr. Endocrinol. Metab. 24 (2017), 611–622.
89. Frumento, D., Nasr, M., El Essawy, B., D'Addio, F., Zuccotti, G.V., Fiorina, P., Immunotherapy for type 1 diabetes. J. Endocrinol. Invest. 40 (2017), 803–814.
90. Ardalan, M., Vahed, S., Gut microbiota and renal transplant outcome. Biomed. Pharmacother. 90 (2017), 229–236.
91. Fricke, W.F., Maddox, C., Song, Y., Bromberg, J.S., Human microbiota characterization in the course of renal transplantation. Am. J. Transplant. 14 (2014), 416–427.
92. Bassi, R., Fiorina, P., Impact of islet transplantation on diabetes complications and quality of life. Curr. Diab. Rep. 11 (2011), 355–363.
93. Yoshifuji, A., Wakino, S., Irie, J., Tajima, T., Hasegawa, K., Kanda, T., Tokuyama, H., Hayashi, K., Itoh, H., Gut Lactobacillus protects against the progression of renal damage by modulating the gut environment in rats. Nephrol. Dial. Transplant. 31 (2016), 401–412.